Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001477" target="_blank" >RIV/00064190:_____/25:10001477 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1002/clt2.70153" target="_blank" >https://doi.org/10.1002/clt2.70153</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/clt2.70153" target="_blank" >10.1002/clt2.70153</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

Popis výsledku v původním jazyce

Background: The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Objective: We aimed to evaluate mepolizumab effectiveness in a real-world cohort from 12 tertiary centers in 6 European countries. Methodology: A retrospective analysis was conducted in 110 CRSwNP patients (comorbid asthma: 86.4%). CRS-related outcomes were analyzed at baseline, 24 and 52 weeks of mepolizumab. Treatment response was evaluated based on EUFOREA 2021 criteria. Results: Significant improvements in NPS, Sinonasal Outcome Test-22 (SNOT-22), and visual analog scale (VAS) symptom scores were observed at 24 and 52 weeks compared to baseline. Further improvement between weeks 24 and 52 was observed for NPS and SNOT-22. Asthma Control Test (ACT) also improved significantly by week 24 (ACT score GREATER-THAN OR EQUAL TO 20: 64.5%). At least one response criterion (change in SNOT-22 GREATER-THAN OR EQUAL TO 8.9, NPS GREATER-THAN OR EQUAL TO 1, VAS total sinus symptoms GREATER-THAN OR EQUAL TO 20, VAS nasal blockage GREATER-THAN OR EQUAL TO 20, VAS loss of smell GREATER-THAN OR EQUAL TO 20) was met by 85.6% and 78.7% of patients at 24 and 52 weeks, respectively. A more stringent composite response (SNOT-22 &lt; 30, NPS &lt; 4, VAS total sinus symptoms &lt; 50, and VAS nasal blockage &lt; 50) was achieved in 18.3% and 44.6% of patients at 24 and 52 weeks, respectively. Conclusion: Mepolizumab demonstrated clinically meaningful benefits in a real-world CRSwNP population, with nearly half of patients achieving a beneficial composite treatment response by week 52. Notably, progressive improvements between weeks 24 and 52 underscore the value of prolonged therapy and the importance of evaluating treatment response at one year. (C) 2026 The Author(s). Clinical and Translational Allergy published by John Wiley &amp; Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Název v anglickém jazyce

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR)

Popis výsledku anglicky

Background: The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Objective: We aimed to evaluate mepolizumab effectiveness in a real-world cohort from 12 tertiary centers in 6 European countries. Methodology: A retrospective analysis was conducted in 110 CRSwNP patients (comorbid asthma: 86.4%). CRS-related outcomes were analyzed at baseline, 24 and 52 weeks of mepolizumab. Treatment response was evaluated based on EUFOREA 2021 criteria. Results: Significant improvements in NPS, Sinonasal Outcome Test-22 (SNOT-22), and visual analog scale (VAS) symptom scores were observed at 24 and 52 weeks compared to baseline. Further improvement between weeks 24 and 52 was observed for NPS and SNOT-22. Asthma Control Test (ACT) also improved significantly by week 24 (ACT score GREATER-THAN OR EQUAL TO 20: 64.5%). At least one response criterion (change in SNOT-22 GREATER-THAN OR EQUAL TO 8.9, NPS GREATER-THAN OR EQUAL TO 1, VAS total sinus symptoms GREATER-THAN OR EQUAL TO 20, VAS nasal blockage GREATER-THAN OR EQUAL TO 20, VAS loss of smell GREATER-THAN OR EQUAL TO 20) was met by 85.6% and 78.7% of patients at 24 and 52 weeks, respectively. A more stringent composite response (SNOT-22 &lt; 30, NPS &lt; 4, VAS total sinus symptoms &lt; 50, and VAS nasal blockage &lt; 50) was achieved in 18.3% and 44.6% of patients at 24 and 52 weeks, respectively. Conclusion: Mepolizumab demonstrated clinically meaningful benefits in a real-world CRSwNP population, with nearly half of patients achieving a beneficial composite treatment response by week 52. Notably, progressive improvements between weeks 24 and 52 underscore the value of prolonged therapy and the importance of evaluating treatment response at one year. (C) 2026 The Author(s). Clinical and Translational Allergy published by John Wiley &amp; Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Translational Allergy

ISSN

2045-7022

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

nestránkováno

Kód UT WoS článku

001704500300001

EID výsledku v databázi Scopus

2-s2.0-105029882392